Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Thrombolysis in Myocardial Infarction Study Group · Harvard University · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
692
total citations
- FWCI
- 54.25
- Percentile
- 100%
- References
- 27
Citations per year
Authors
13- JLJ. L. MegaCorresponding
Thrombolysis in Myocardial Infarction Study Group, Harvard University, Brigham and Women's Hospital
- EBEugene Braunwald
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard University
- SMSatishkumar Mohanavelu
Thrombolysis in Myocardial Infarction Study Group
- PBPaul Burton
Johnson & Johnson (United States)
- RPRohan Poulter
Royal Brisbane and Women's Hospital
Topics & keywords
Topics
Keywords
- TIMI
- Medicine
- Rivaroxaban
- Placebo
- Internal medicine
- Acute coronary syndrome
- Cardiology
- Double blind
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.